November 17, 2026
Press Pass USA
YOUR NEWS. YOUR AMERICA.
Health

FDA grants accelerated approval to Nelkarmi, a new option for hard-to-treat ALK-positive lung cancer

Washington  •  November 17, 2026  •  By Press Pass USA
Capsules, a stethoscope and a clipboard marked Lung Cancer ServicesPhoto: Curtin University (file photo)

The U.S. Food and Drug Administration granted accelerated approval on Tuesday to neladalkib, sold as Nelkarmi, for adults with advanced ALK-positive lung cancer that has already been treated with other targeted drugs, giving patients whose tumors grew after earlier therapy a new once-daily pill.

The approval covers adults with locally advanced or metastatic ALK-positive non-small cell lung cancer, or NSCLC, that cannot be removed by surgery and who previously received either alectinib as their only prior ALK-targeted drug, or two or more ALK-targeted drugs plus platinum-based chemotherapy.

ALK-positive lung cancer is a subset of the disease driven by a rearrangement in the ALK gene. When the cancer grows despite treatment with earlier ALK-targeted drugs, options are limited. Neladalkib, a kinase inhibitor developed by Nuvalent, was designed to address resistance to those earlier drugs, including mutations linked to resistance to lorlatinib.

The decision rests on the ALKOVE-1 trial, a global Phase I/II study in which all patients received neladalkib. Among 67 patients whose only prior ALK drug was alectinib, tumors shrank in 49 percent of patients. Of those who responded, 76 percent had responses lasting at least six months and 52 percent had responses lasting at least a year.

Among 155 more heavily treated patients — those who had received two or more ALK-targeted drugs plus platinum chemotherapy — tumors shrank in 32 percent of patients, with 69 percent of responders maintaining their response for at least six months and 51 percent for at least a year.

The trial results were presented at the 2026 American Society of Clinical Oncology annual meeting and published in the Journal of Clinical Oncology.

The recommended dose is 150 milligrams taken by mouth once a day, with or without food, until the disease progresses or side effects become unacceptable.

The drug's prescribing information carries warnings for liver toxicity, kidney toxicity, eye toxicity, elevated creatine phosphokinase and harm to an unborn baby. The most common side effects, seen in at least 20 percent of patients, were liver toxicity, muscle and bone pain, constipation, altered taste, peripheral neuropathy, swelling and fatigue.

Because the approval is accelerated, it is based on tumor shrinkage and how long responses lasted, rather than proof of longer survival. Confirmatory trials are required, and continued approval may depend on their results.

The application received priority review, and neladalkib had previously been granted breakthrough therapy and orphan drug designations. The approval came 10 days ahead of the FDA's November 27 target date. GSK, which announced the approval, said it was the company's second lung cancer approval this year.

Sources: U.S. Food and Drug Administration, "FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer" (Nov. 17, 2026, full text verified); OncLive, "FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC" (Nov. 17, 2026, full text verified); Cancer Network, "FDA Approves Neladalkib in Advanced ALK+ Non–Small Cell Lung Cancer" (Nov. 17, 2026, full text verified); GSK, "Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer" (Nov. 17, 2026, full text verified).

Sponsored Mr Cat
MR CAT ADVERTISINGDOES YOUR BUSINESS NEED MORE CUSTOMERS?
VISIT SITE →
← Back to homepage